NovelStem International Corp. (NSTM)
Oxford Ledge is still expanding full research coverage of NSTM. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
NovelStem is a holding company with remaining rights to future profits from stem cell technology previously developed by its liquidated subsidiary.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 10-K Annual financial report with audited statements 2026-03-26
- 10-Q Quarterly financial report (unaudited) 2025-11-12
- 10-Q Quarterly financial report (unaudited) 2025-08-06
- 10-Q Quarterly financial report (unaudited) 2025-05-19
Source: SEC EDGAR.
- Open NSTM in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.